MIVAC Development as part of the Universal Influenza Vaccine (UNIFLUVAC) network, was supported by the FP7-PEOPLE-2013-ITN grant.
MIVAC Development creates a new company, Toleranzia AB, for the spin-out of the tolerance inducing Re-TolerogenTM platform.
MIVAC development receives continued financial support from Innovationskontor Väst for the tolerance inducing Re-TolerogenTM platform.
MIVAC Development creates a new company, Alzinova AB, for the spin-out of the AβCCTM-project.
Synthon and MIVAC Development enter into exclusive research collaboration and commercial licensing agreement in multiple sclerosis.
MIVAC Development announces an opening in the area of molecular biology to strengthen the team working on our tolerance-inducing technology platform.
MIVAC Development receives verification grants from Innovationskontor Väst for both the AβCCTM-project and for the tolerance inducing Re-TolerogenTM platform.
MIVAC Development receives verification grant from GöteborgBIO and Sahlgrenska Science Park (SSP).
The AβCCTM invention receives attention on the Alzheimer Research Forum webpage.
MIVAC researchers publishes data on covalently stabilized amyloid-β aggregates.